BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 34144044)

  • 1. COVID-19 Vaccination Is Safe and Effective in Patients With Inflammatory Bowel Disease: Analysis of a Large Multi-institutional Research Network in the United States.
    Hadi YB; Thakkar S; Shah-Khan SM; Hutson W; Sarwari A; Singh S
    Gastroenterology; 2021 Oct; 161(4):1336-1339.e3. PubMed ID: 34144044
    [No Abstract]   [Full Text] [Related]  

  • 2. Methotrexate for inflammatory bowel disease: time for reconsideration.
    Nielsen OH; Ainsworth MA; Steenholdt C
    Expert Rev Gastroenterol Hepatol; 2019 May; 13(5):407-409. PubMed ID: 30895827
    [No Abstract]   [Full Text] [Related]  

  • 3. Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease.
    Renna S; Cottone M; Orlando A
    World J Gastroenterol; 2014 Aug; 20(29):9675-90. PubMed ID: 25110407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expert opinion: experience with 6-mercaptopurine in the treatment of inflammatory bowel disease.
    Korelitz BI
    World J Gastroenterol; 2013 May; 19(20):2979-84. PubMed ID: 23716977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preventing infective complications in inflammatory bowel disease.
    Mill J; Lawrance IC
    World J Gastroenterol; 2014 Aug; 20(29):9691-8. PubMed ID: 25110408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease.
    Hyams JS; Dubinsky MC; Baldassano RN; Colletti RB; Cucchiara S; Escher J; Faubion W; Fell J; Gold BD; Griffiths A; Koletzko S; Kugathasan S; Markowitz J; Ruemmele FM; Veereman G; Winter H; Masel N; Shin CR; Tang KL; Thayu M
    Gastroenterology; 2017 Jun; 152(8):1901-1914.e3. PubMed ID: 28193515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolving Considerations for Thiopurine Therapy for Inflammatory Bowel Diseases-A Clinical Practice Update: Commentary.
    Hanauer SB; Sandborn WJ; Lichtenstein GR
    Gastroenterology; 2019 Jan; 156(1):36-42. PubMed ID: 30195449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Humoral Immune Response to Messenger RNA COVID-19 Vaccines Among Patients With Inflammatory Bowel Disease.
    Kappelman MD; Weaver KN; Boccieri M; Firestine A; Zhang X; Long MD;
    Gastroenterology; 2021 Oct; 161(4):1340-1343.e2. PubMed ID: 34144046
    [No Abstract]   [Full Text] [Related]  

  • 9. Humoral response to COVID-19 infection in immunosuppressed patients with inflammatory bowel disease.
    Scharrer S; Kutschera M; Weseslindtner L; Primas C; Vogelsang H
    Eur J Gastroenterol Hepatol; 2021 Mar; 33(3):443-447. PubMed ID: 33522752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased arterial stiffness in inflammatory bowel diseases is dependent upon inflammation and reduced by immunomodulatory drugs.
    Zanoli L; Rastelli S; Inserra G; Lentini P; Valvo E; Calcagno E; Boutouyrie P; Laurent S; Castellino P
    Atherosclerosis; 2014 Jun; 234(2):346-51. PubMed ID: 24732573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of anti-tumor necrosis factor therapy during pregnancy in patients with inflammatory bowel disease.
    Androulakis I; Zavos C; Christopoulos P; Mastorakos G; Gazouli M
    World J Gastroenterol; 2015 Dec; 21(47):13205-11. PubMed ID: 26715803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytomegalovirus reactivation in inflammatory bowel disease: an uncommon occurrence related to corticosteroid dependence.
    Hissong E; Chen Z; Yantiss RK
    Mod Pathol; 2019 Jul; 32(8):1210-1216. PubMed ID: 30952971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Should my patient with inflammatory bowel disease on immunosuppressive therapy be vaccinated against influenza virus?
    Narula N; Yamamura DL; Marshall JK
    Can J Gastroenterol; 2010 Feb; 24(2):121-5. PubMed ID: 20151071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment.
    Quetglas EG; Armuzzi A; Wigge S; Fiorino G; Barnscheid L; Froelich M; Danese S
    Eur J Clin Pharmacol; 2015 Jul; 71(7):773-99. PubMed ID: 26008212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary sclerosing cholangitis associated with inflammatory bowel disease: an observational study in a Southern Europe population focusing on new therapeutic options.
    Franceschet I; Cazzagon N; Del Ross T; D'Incà R; Buja A; Floreani A
    Eur J Gastroenterol Hepatol; 2016 May; 28(5):508-13. PubMed ID: 26872110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of the COVID-19 outbreak and the serum prevalence of SARS-CoV-2 antibodies in patients with inflammatory bowel disease treated with biologic drugs.
    Bossa F; Carparelli S; Latiano A; Palmieri O; Tavano F; Panza A; Pastore M; Marseglia A; D'Altilia M; Latiano T; Corritore G; Martino G; Nardella M; Guerra M; Terracciano F; Sacco M; Perri F; Andriulli A
    Dig Liver Dis; 2021 Mar; 53(3):277-282. PubMed ID: 33423942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of COVID-19 pandemic on the management of paediatric inflammatory bowel disease: An Italian multicentre study on behalf of the SIGENP IBD Group.
    Arrigo S; Alvisi P; Banzato C; Bramuzzo M; Celano R; Civitelli F; D'Arcangelo G; Dilillo A; Dipasquale V; Felici E; Fuoti M; Gatti S; Knafelz D; Lionetti P; Mario F; Marseglia A; Martelossi S; Moretti C; Norsa L; Panceri R; Renzo S; Romano C; Romeo E; Strisciuglio C; Martinelli M
    Dig Liver Dis; 2021 Mar; 53(3):283-288. PubMed ID: 33388247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes with ustekinumab as rescue treatment in therapy-refractory or therapy-intolerant ulcerative colitis.
    Ochsenkühn T; Tillack C; Szokodi D; Janelidze S; Schnitzler F
    United European Gastroenterol J; 2020 Feb; 8(1):91-98. PubMed ID: 32213052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retention Rate, Persistence and Safety of Adalimumab in Inflammatory Bowel Disease: A Real-Life, 9-Year, Single-Center Experience in Italy.
    Sartini A; Scaioli E; Liverani E; Bellanova M; Ricciardiello L; Bazzoli F; Belluzzi A
    Dig Dis Sci; 2019 Mar; 64(3):863-874. PubMed ID: 30334112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The risk for opportunistic infections in inflammatory bowel disease with biologics: an update.
    Borman ZA; Côté-Daigneault J; Colombel JF
    Expert Rev Gastroenterol Hepatol; 2018 Nov; 12(11):1101-1108. PubMed ID: 30277409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.